PHARMACOKINETIC CHARACTERIZATION AND PRELIMINARY EXPOSURE-SAFETY/RESPONSE ANALYSIS OF A NOVEL PKC INHIBITOR LXS196 IN A PHASE I STUDY IN METASTATIC UVEAL MELANOMA PATIENTS.

Zhu X.; Roy M.; Gonzalez-Maffe J.; Yerramilli-Rao P.; Burks H.

首页> 外文期刊>Clinical Pharmacology and Therapeutics >PHARMACOKINETIC CHARACTERIZATION AND PRELIMINARY EXPOSURE-SAFETY/RESPONSE ANALYSIS OF A NOVEL PKC INHIBITOR LXS196 IN A PHASE I STUDY IN METASTATIC UVEAL MELANOMA PATIENTS.

【24h】

PHARMACOKINETIC CHARACTERIZATION AND PRELIMINARY EXPOSURE-SAFETY/RESPONSE ANALYSIS OF A NOVEL PKC INHIBITOR LXS196 IN A PHASE I STUDY IN METASTATIC UVEAL MELANOMA PATIENTS.

机译：一种新型PKC抑制剂LXS196中的药代动力学表征及初步暴露 - 安全/响应分析在我肝癌患者中的研究中研究。

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Clinical Pharmacology and Therapeutics》 |2019年第1期|共1页
作者
Zhu X.; Roy M.; Gonzalez-Maffe J.; Yerramilli-Rao P.; Burks H.;
展开▼
作者单位

Novartis Inst BioMed Res Cambridge MA USA;

Novartis Pharmaceut E Hanover NJ USA;

Novartis Pharma AG Basel Switzerland;

Novartis Inst BioMed Res Cambridge MA USA;

Novartis Inst BioMed Res Cambridge MA USA;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类药理学;
关键词

相似文献

外文文献
中文文献
专利

1. PHARMACOKINETIC CHARACTERIZATION AND PRELIMINARY EXPOSURE-SAFETY/RESPONSE ANALYSIS OF A NOVEL PKC INHIBITOR LXS196 IN A PHASE I STUDY IN METASTATIC UVEAL MELANOMA PATIENTS. [J] . Zhu X., Roy M., Gonzalez-Maffe J., Clinical Pharmacology and Therapeutics . 2019,第Suppla1期

机译：一种新型PKC抑制剂LXS196中的药代动力学表征及初步暴露 - 安全/响应分析在我肝癌患者中的研究中研究。
2. Receiver operating characteristic analysis: calculation for the marker 'melanoma inhibitory activity' in metastatic uveal melanoma patients. [J] . Klingenstein A, Haritoglou I, Schaumberger MM, Melanoma research . 2011,第4期

机译：接收者工作特征分析：计算转移性葡萄膜黑色素瘤患者的标志物“黑色素瘤抑制活性”。
3. The multikinase inhibitor midostaurin (PKC412A) lacks activity in metastatic melanoma: a phase IIA clinical and biologic study [J] . M J Millward, C House, D Bowtell, British Journal of Cancer . 2006,第7期

机译：多激酶抑制剂Midostaurin（PKC412A）在转移性黑色素瘤中缺乏活性：IIA期临床和生物学研究
4. Ultrasound Tissue Characterization for Non-Invasive Assessment of Metastatic Risk Potential in Uveal Malignant Melanoma [C] . D.J. COLEMAN, R.H. SILVERMAN, F.L. LIZZI, International Society for Diagnostic Ultrasonics in Ophthalmology Meeting . 2003

机译：无侵袭性评估乌斯敏黑色素瘤的转移性风险潜力的超声组织特征
5. Associating Computed Tomography (CT) Imaging Response Criteria and Texture Analysis Measurements with Survival in Patients with Metastatic Melanoma Treated with Anti-angiogenic Therapy. [D] . Gray, Mark Russell. 2014

机译：将计算机断层扫描（CT）成像反应标准和纹理分析测量值与接受抗血管生成治疗的转移性黑色素瘤患者的生存率相关联。
6. The multikinase inhibitor midostaurin (PKC412A) lacks activity in metastatic melanoma: a phase IIA clinical and biologic study [O] . M J Millward, C House, D Bowtell, 2006

机译：多激酶抑制剂Midostaurin（PKC412A）在转移性黑色素瘤中缺乏活性：IIA期临床和生物学研究
7. A phase II study of the insulin-like growth factor type I receptor inhibitor IMC-A12 in patients with metastatic uveal melanoma [O] . Jane Mattei, Alexej Ballhausen, Roland Bassett, 2020

机译：胰岛素样生长因子I型受体抑制剂IMC-A12在转移性UVEAL melanoma患者中的II期研究

PHARMACOKINETIC CHARACTERIZATION AND PRELIMINARY EXPOSURE-SAFETY/RESPONSE ANALYSIS OF A NOVEL PKC INHIBITOR LXS196 IN A PHASE I STUDY IN METASTATIC UVEAL MELANOMA PATIENTS.

著录项

相似文献

相关主题

期刊订阅